Combination immunotherapy targeting multiple immune checkpoints such as CTLA-4 and PD-(L)1, has been expected to increase therapeutic efficacy,4 given that the majority of patients with head and neck cancer either fail to respond or relapse with PD-(L)1 blockade as a single agent.5 This evidence concerns the gene CD274 and head and neck cancer.